Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
The shift to Mateon Therapeutics reflected a broader focus on "Vascular Targeted Therapy" (VTT), which combines VDAs with anti-angiogenic agents to trap and destroy tumor cores while preventing new vessel growth. Historical Acquisitions: Oxigene
A second-generation VDA focused on hematologic malignancies; initiated Phase 1b/2 trials in 2015. Myopic Macular Degeneration OXi4503 A key Phase II trial showed that
Lead candidate; received and Orphan Drug designations for platinum-resistant ovarian cancer. OXi4503 in a stock-for-stock merger to bolster its cash
A key Phase II trial showed that a combination of CA4P and Avastin significantly improved progression-free survival in ovarian cancer patients compared to Avastin alone.
In 2009, OXiGENE re-acquired full rights to its lead candidates, ZYBRESTAT and OXi4503, from Symphony ViDA. Lead Pharmaceutical Pipeline
In 2010, OXiGENE acquired VaxGen, Inc. in a stock-for-stock merger to bolster its cash reserves by approximately $33 million.